Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics Plc. (ADAP)
:ADAP
RESEARCH TOOLSreports
ADAP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.53 - $2.05
Previous CloseN/A
Volume813.54K
Average Volume (3M)882.67K
Market Cap
$149.00M
Enterprise Value$131.49M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Feb 27, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding255,883,210
10 Day Avg. Volume577,888
30 Day Avg. Volume882,668
Standard Deviation0.38
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.85
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.61
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$3.50Price Target Upside503.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Adaptimmune Therapeutics News
PremiumCompany Announcements
Adaptimmune Therapeutics Announces Key Leadership Changes
PremiumCompany Announcements
Adaptimmune’s Strategic Shift and Financial Update
PremiumPre-Earnings
Is ADAP a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessADAP received positive pivotal study results for its lete-cel program, which boosts confidence in its treatment for specific cancer types.
Market PotentialUpcoming milestones include a potential lete-cel commercial launch and submissions that could enhance the company's market position.
Therapy EffectivenessLete-cel demonstrated an overall response rate of 42% for sarcoma patients, significantly higher than current therapies achieving only 4-7%.
Bears Say
Program DiscontinuationThe discontinuation of enrollment in the SURPASS-3 study due to a reallocation of resources means the full dataset anticipated in 2026 will no longer be available.
Revenue ChallengesZero sales were reported for the Tecelra launch, and no meaningful revenue is expected shortly.
Workforce ReductionA 33% workforce reduction was announced as a necessary measure to help the company achieve break-even.
---
Ownership Overview
48.53% Insiders
0.10% Mutual Funds
0.01% Other Institutional Investors
51.10% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADAP FAQ
What was Adaptimmune Therapeutics Plc.’s price range in the past 12 months?
Adaptimmune Therapeutics Plc. lowest stock price was $0.53 and its highest was $2.05 in the past 12 months.
What is Adaptimmune Therapeutics Plc.’s market cap?
Adaptimmune Therapeutics Plc.’s market cap is $149.00M.
When is Adaptimmune Therapeutics Plc.’s upcoming earnings report date?
Adaptimmune Therapeutics Plc.’s upcoming earnings report date is Feb 27, 2025 which is in 7 days.
How were Adaptimmune Therapeutics Plc.’s earnings last quarter?
Adaptimmune Therapeutics Plc. released its earnings results on Nov 13, 2024. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.001.
Is Adaptimmune Therapeutics Plc. overvalued?
According to Wall Street analysts Adaptimmune Therapeutics Plc.’s price is currently Undervalued.
Does Adaptimmune Therapeutics Plc. pay dividends?
Adaptimmune Therapeutics Plc. does not currently pay dividends.
What is Adaptimmune Therapeutics Plc.’s EPS estimate?
Adaptimmune Therapeutics Plc.’s EPS estimate is -0.03.
How many shares outstanding does Adaptimmune Therapeutics Plc. have?
Adaptimmune Therapeutics Plc. has 255,883,210 shares outstanding.
What happened to Adaptimmune Therapeutics Plc.’s price movement after its last earnings report?
Adaptimmune Therapeutics Plc. reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went down -23.377%.
Which hedge fund is a major shareholder of Adaptimmune Therapeutics Plc.?
Currently, no hedge funds are holding shares in ADAP
---
Adaptimmune Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (503.45% Upside)
$3.50 (503.45% Upside)
Blogger Sentiment
Bullish
ADAP Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 10.3%
Last 30 Days ▲ 10.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.83%
12-Months-Change
Fundamentals
Return on Equity
-56.17%
Trailing 12-Months
Asset Growth
7.01%
Trailing 12-Months
Company Description
Adaptimmune Therapeutics Plc.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
---
ADAP Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong results from clinical trials and a successful product launch, alongside strategic restructuring to achieve financial stability. However, challenges include significant job cuts and discontinuation of certain programs.Read More>---
ADAP Stock 12 Month Forecast
Average Price Target
$3.50
▲(503.45% Upside)
Technical Analysis
Gilead Sciences
―
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Immatics
―
Best Analysts Covering ADAP
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+18.51%
reiterated a sell rating 3 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +18.51% per trade.
---